Posts Tagged ‘buzz stocks’

China Security and Surveillance Technology, Inc. (CSR)- Buzz Stock of the Day

Monday, July 26th, 2010

Shares of China Security and Surveillance Technology, Inc. (NYSE: CSR) were up almost 13 percent from Friday’s closing price in morning trading on Monday after the company posted strong second quarter earnings thanks in part to large scale government projects, increased demand, and improved margins.

The Shenzhen-based China Security and Surveillance Technology, Inc. reported second quarter net income of $17.81 million, or 23 cents per diluted share, marking a 174 percent increase in net income and a 76.9 percent increase in diluted earnings per share. Revenues for the quarter increased 18.6 percent to $168.35 million, over the prior year.

Analysts on average were expecting earnings of 23 cents a share on revenue of $177.8 million, according to Thomson Reuters I/B/E/S.
[–quote–]
“Our results demonstrate the great strength of CSST’s assets and our ability to execute with focus and discipline,” said Guoshen Tu, Chairman and CEO of China Security and Surveillance Technology, Inc. in a statement. “Revenues and earnings growth continue to be solid, our margin improvement is encouraging, major growth and cost initiatives are on track, and we continue to execute on large-scale government projects from safe cities and e-cities in China.”

For fiscal 2010, the company reaffirmed its earnings forecast of $1.12 a share to $1.16 a share on revenue of $830 million to $850 million.

Analysts on average are expecting earnings of $1.10 a share, on revenue of $817 million.

“Underneath the terrific industry demand for surveillance and safety products and services in China, we’re optimistic about CSST’s prospect to continue to lead the industry in China,” said Tu. “We believe our market leadership extends across the industry’s broadest portfolio of products and services in China. Our scale and reach in China will provide meaningful and sustainable competitive advantages for us to capitalize on in the years ahead. Together with our sharp focus on high-growth initiatives, we have a tremendous set of assets and an impressive record in terms of executing and delivering on targets. I am very confident in our ability to deliver strong results in 2010.”

Infinera Corp. (INFN) – Buzz Stock of the Day

Friday, July 23rd, 2010

Shares of optical networking systems developer, Infinera Corp. (Nasdaq: INFN) rallied more than 26 percent from Thursday’s closing price, in morning trading on Friday after the company posted a smaller second quarter net loss and higher revenue over the same period a year ago.

For the three months ended June 26, the company posted a net loss of $9.6 million, or 10 cents per share, compared with a loss of $27.1 million, or 28 cents per share, in the same period a year earlier. Infinera’s revenue rose 62 percent to $111.4 million, from $68.9 million a year ago. Excluding stock compensation expenses, Infinera earned 3 cents per share in the latest quarter.

[–quote–]

Analysts, on average, expected a loss of 5 cents per share on revenue of $99.5 million, according to a poll by Thomson Reuters. Analyst estimates exclude stock options costs.

“We achieved new records for overall quarterly revenue and bookings, including increased shipments of tributary adapter modules, and we posted higher gross margins, achieved positive cash flow, and earned a profit on a non-GAAP basis,” said Infinera’s CEO, Tom Fallon in a statement.

Additional highlights from the quarter include positive cash from operations of $11.2 million, and higher gross margins (42% vs. 39% for the same period a year ago).

Infinera expects Q3 revenue in the range of  $125 million and $128 million, gross margins of approximately 45 percent to 47 percent, and earnings of between $0.07 and $0.10 per share, on a non-GAAP basis.

Harley-Davidson, Inc. (HOG) – Buzz Stock of the Day

Tuesday, July 20th, 2010

Shares of motorcycle maker, Harley-Davidson, Inc. (NYSE: HOG) were up as much as 14 percent from Monday’s closing price, in morning trading on Tuesday after the company announced a profit at its motorcycle financing unit and stabilizing motorcycle sales in the second quarter.

Harley-Davidson Financial Services, the business unit that gives loans to Harley customers and dealers posted operating income of $60.8 million in the quarter, up from a loss of $90.5 million in the same quarter last year. Harley’s net income for the three months ended June 27 was $71.2 million, or 30 cents per share, up from $19.8 million, or 8 cents per share in the same quarter a year ago. Excluding discontinued operations, profit was 59 cents per share. Analysts polled by Thomson Reuters expected profit of 41 cents per share, on average.
[–quote–]

Harley-Davidson’s second quarter revenue from motorcycles and related products was flat at $1.14 billion. Analysts expected revenue of $1.13 billion.

“Over the past year-and-a-half, we’ve taken many actions, from an operations standpoint, in marketing and product development at HDFS and in every aspect of our business to deal with the economy and focus our resources on long-term goals and priorities,” said CEO Keith Wandell in the company’s earnings call. “Harley-Davidson’s first half earnings from continuing operations were $0.89 a share. We saw continued improvement at HDFS and there was a further moderation in the retail sales decline for new Harley-Davidson motorcycle sales in the second quarter.”

The Milwaukee-based Harley-Davidson a major overhaul at the start of 2009 to cope with a shrinking market and an economic downturn that has undercut demand for its pricey, chrome-laden bikes. Sales of Harley motorcycles, whose prices range from $7,000 to $25,000 can take a big hit when the economy goes south. The company has been focused on cutting costs and streamlining its business. Last year, it announced the shutdown its Buell sport-bike line and said it planned to sell the Italian motorcycle maker MV Agusta. In December, the company and its union agreed to a cost-cutting contract at its main motorcycle plant in York, Pa., that involved layoffs for about half the company’s unionized work force there.

The next step in its restructuring plan comes this week, when Harley-Davidson executives begin negotiations with the company’s union in Wisconsin for a new contract. Wandell said the company is “not flexible” on its demands and reiterated that the company will move Wisconsin production elsewhere if it doesn’t get the cost-savings it wants, which include lower expenses at its powertrain factory in Milwaukee and its motorcycle components facility in Tomahawk, Wis.

Keryx Biopharmaceuticals, Inc. (KERX) – Hot Buzz Stock of the Day

Wednesday, July 14th, 2010

Shares of Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) climbed as much as 17 percent in morning trading Wednesday after the after the company announced its experimental childhood cancer drug, KRX-0401 (perifosine), had received Orphan Drug designation from U.S. Food and Drug Administration (FDA).

Commenting on receiving Orphan Drug designation, Ron Bentsur, Chief Executive Officer of Keryx stated, “We are currently exploring next steps for the development of perifosine in this indication which we hope, ultimately, could provide a new treatment option for children and infants suffering with neuroblastoma.

The FDA grants Orphan Drug status to new drugs that treat a rare disease afflicting fewer than 200,000 patients in the U.S. The benefits of Orphan Drug designation include seven-year marketing exclusivity if the drug is the first of its kind approved, tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance and waiver of Prescription Drug User Fee Act (PDUFA) filing fees.

KRX-0401 is being developed for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants. Although it is a rare form of cancer, neuroblastoma accounts for approximately 7 percent of all cancer deaths among children.

[–quote–]

Clinical Phase 1 data was presented last month in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Investigators from the Memorial Sloan-Kettering Cancer Center concluded that perifosine was demonstrated to be safe and well tolerated in children with advanced solid tumors and that perifosine may have antitumor clinical activity as a single agent in neuroblastoma.

Additionally, the Nationaly Cancer Institute recently published a preclinical study that found perifosine showed a statistically significant reduction in neuroblastoma cell survival, slowed or regressed tumor growth, and increased survival in mice bearing neuroblastoma tumors.

Vivus, Inc. (VVUS) – Buzz Stock of the Day

Tuesday, July 13th, 2010

Shares of weight loss drug maker, VIVUS, Inc. (Nasdaq: VVUS) surged as much as 13 percent from Monday’s closing price, in morning trading on Tuesday after the U.S. Food and Drug Administration released documents that showed FDA researchers believe that use of Vivus’ diet drug Qnexa can result in “significant” weight loss. However, the agency raised questions about the drug’s safety.

Vivus shares were up about 34% to $14.25 in Tuesday’s pre-market trading session.

[–quote–]

In the FDA’s review of Qnexa, posted online Tuesday as part of the briefing documents for Thursday’s advisory panel, pooled data from two large phase III studies demonstrated that patients treated with low, medium and high doses Qnexa lost between 3 percent, 7 percent and 9 percent of their body weight, respectively, adjusted for the weight-loss reported for patients treated with a placebo.

Qnexa’s safety and not the drug’s ability to help patients lose weight, was the major concern entering Thursday’s meeting. In its briefing document Tuesday, FDA’s safety review highlights five areas of “particular interest” related to Qnexa — pregnancy risk, psychiatric-related adverse events, cognitive-related adverse events, metabolic acidosis and cardiovascular events. Many of these concerns, however, were expected.

Vivus, in its own briefing documents, said research showing that 68 percent of adults in the U.S. are overweight indicate a clear medical need for Qnexa.

A panel of experts is scheduled to review the drug on Thursday, with the FDA making a regulatory decision in October.